US Pharma MarketingAfter his predecessor's turbulent tenure, Karim Mikhail is working to restore staff morale and revisit controversial rejections. FDA smoking Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Exclusive Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapter With meetings of…
In a recent town hall meeting, Karim Mikhail told Food and Drug Administration staff that he was normal.
“I am with you on planet Earth,” he said in June. “I understand very well what everybody is going through.”
Typically, such an acknowledgment would be unremarkable. But Mikhail is acting director of the FDA’s Center for Biologics Evaluation and Research, where the previous leader, Vinay Prasad, was decidedly outside the norm.
Source: STAT News Pharma